Cargando…
Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is to blame for about 60% of dementia cases worldwide. The blood–brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimeti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005336/ https://www.ncbi.nlm.nih.gov/pubmed/36903581 http://dx.doi.org/10.3390/molecules28052336 |
_version_ | 1784905054930599936 |
---|---|
author | Zhong, Xinyu Na, Yue Yin, Shun Yan, Chang Gu, Jinlian Zhang, Ning Geng, Fang |
author_facet | Zhong, Xinyu Na, Yue Yin, Shun Yan, Chang Gu, Jinlian Zhang, Ning Geng, Fang |
author_sort | Zhong, Xinyu |
collection | PubMed |
description | Alzheimer’s disease (AD) is to blame for about 60% of dementia cases worldwide. The blood–brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimetic nanoparticles (NPs) to solve this situation. Among them, NPs can extend the half-life of drugs in the body as the “core” of the wrapped drug, and the cell membrane acts as the “shell” of the wrapped NPs to functionalize the NPs, which can further improve the delivery efficiency of nano-drug delivery systems. Researchers are learning that cell membrane biomimetic NPs can circumvent the BBB’s restriction, prevent harm to the body’s immune system, extend the period that NPs spend in circulation, and have good biocompatibility and cytotoxicity, which increases efficacy of drug release. This review summarized the detailed production process and features of core NPs and further introduced the extraction methods of cell membrane and fusion methods of cell membrane biomimetic NPs. In addition, the targeting peptides for modifying biomimetic NPs to target the BBB to demonstrate the broad prospects of cell membrane biomimetic NPs drug delivery systems were summarized. |
format | Online Article Text |
id | pubmed-10005336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100053362023-03-11 Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease Zhong, Xinyu Na, Yue Yin, Shun Yan, Chang Gu, Jinlian Zhang, Ning Geng, Fang Molecules Review Alzheimer’s disease (AD) is to blame for about 60% of dementia cases worldwide. The blood–brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimetic nanoparticles (NPs) to solve this situation. Among them, NPs can extend the half-life of drugs in the body as the “core” of the wrapped drug, and the cell membrane acts as the “shell” of the wrapped NPs to functionalize the NPs, which can further improve the delivery efficiency of nano-drug delivery systems. Researchers are learning that cell membrane biomimetic NPs can circumvent the BBB’s restriction, prevent harm to the body’s immune system, extend the period that NPs spend in circulation, and have good biocompatibility and cytotoxicity, which increases efficacy of drug release. This review summarized the detailed production process and features of core NPs and further introduced the extraction methods of cell membrane and fusion methods of cell membrane biomimetic NPs. In addition, the targeting peptides for modifying biomimetic NPs to target the BBB to demonstrate the broad prospects of cell membrane biomimetic NPs drug delivery systems were summarized. MDPI 2023-03-03 /pmc/articles/PMC10005336/ /pubmed/36903581 http://dx.doi.org/10.3390/molecules28052336 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhong, Xinyu Na, Yue Yin, Shun Yan, Chang Gu, Jinlian Zhang, Ning Geng, Fang Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease |
title | Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease |
title_full | Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease |
title_fullStr | Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease |
title_full_unstemmed | Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease |
title_short | Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease |
title_sort | cell membrane biomimetic nanoparticles with potential in treatment of alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005336/ https://www.ncbi.nlm.nih.gov/pubmed/36903581 http://dx.doi.org/10.3390/molecules28052336 |
work_keys_str_mv | AT zhongxinyu cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease AT nayue cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease AT yinshun cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease AT yanchang cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease AT gujinlian cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease AT zhangning cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease AT gengfang cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease |